The iWorld

Onconase is being regarded now a days by medical community as an early-stage solution and treatment to potentially prevent the outbreak and growth of mesothelioma which is a a rare cancer that is usually caused by asbestos exposure.

Onconase is expected to help reduce the doses of existing chemotherapy drugs required in those specific patients sufffering from the disease who develop the cancer disease.

Onconase is very soon to be is clinically validated, as results from a pivotal Phase 3b trial are expected in third quarter of this year.

Onconase is presently being scrutinized in an international Phase 3b registration trial in patients that are affected and suffering from inoperable malignant mesothelioma, and it was granted an orphan drug designation by FDA for this indication in January..